Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher William Murray is active.

Publication


Featured researches published by Christopher William Murray.


Journal of Computer-aided Molecular Design | 2002

Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase

Louise Birch; Christopher William Murray; Michael J. Hartshorn; Ian J. Tickle; Marcel L. Verdonk

Many proteins undergo small side chain or even backbone movements on binding of different ligands into the same protein structure. This is known as induced fit and is potentially problematic for virtual screening of databases against protein targets. In this report we investigate the limits of the rigid protein approximation used by the docking program, GOLD, through cross-docking using protein structures of influenza neuraminidase. Neuraminidase is known to exhibit small but significant induced fit effects on ligand binding. Some neuraminidase crystal structures caused concern due to the bound ligand conformation and GOLD performed poorly on these complexes. A `clean set, which contained unique, unambiguous complexes, was defined. For this set, the lowest energy structure was correctly docked (i.e. RMSD < 1.5 xa0Å away from the crystal reference structure) in 84% of proteins, and the most promiscuous protein (1mwe) was able to dock all 15 ligands accurately including those that normally required an induced fit movement. This is considerably better than the 70% success rate seen with GOLD against general validation sets. Inclusion of specific water molecules involved in water-mediated hydrogen bonds did not significantly improve the docking performance for ligands that formed water-mediated contacts but it did prevent docking of ligands that displaced these waters. Our data supports the use of a single protein structure for virtual screening with GOLD in some applications involving induced fit effects, although care must be taken to identify the protein structure that performs best against a wide variety of ligands. The performance of GOLD was significantly better than the GOLD implementation of ChemScore and the reasons for this are discussed. Overall, GOLD has shown itself to be an extremely good, robust docking program for this system.


Archive | 2003

3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors

Christopher William Murray; Michael J. Hartshorn; Martyn Frederickson; Miles Congreve; Alessandro Padova; Steven John Woodhead; Adrian Liam Gill; Andrew James Woodhead


Archive | 2017

composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase

Christopher William Murray; Gilbert Ebai Besong; Gordon Saxty; Lieven Meerpoel; Oliver Alexis Georges Querolle; Steven John Woodhead; Valerio Berdini; Virginie Sophie Poncelet


Archive | 2017

BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS

Valerio Berdini; Ildiko Maria Buck; James E. H. Day; Charlotte Mary Griffiths-Jones; Thomas Daniel Heightman; Steven Howard; Christopher William Murray; David Norton; Marc O'Reilly; Alison Jo-Anne Woolford; Michael Cooke; David Cousin; Stuart Thomas Onions; Jonathan Shannon; John P. Watts


Archive | 2016

Compuestos bicíclicos heterocíclicos como inhibidores de la proteína tirosina quinasa

Gordon Saxty; Valerio Berdini; Christopher William Murray; Charlotte Mary Griffiths-Jones; Emma Vickerstaffe; Gilbert Ebai Besong; Maria Grazia Carr


Archive | 2015

IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS)

Gordon Saxty; Christopher William Murray; Valerio Berdini; Lee W. Page; Susan Roomans; Emiliano Tamanini; Ildiko Maria Buck; James E. H. Day; Maria Grazia Carr; Lydia Y. W. Lee


Archive | 2011

Inhibiteurs de pyrazolyl-quinazoline kinase

Gordon Saxty; Christopher William Murray; Valerio Berdini; Gilbert Ebai Besong; Christopher Charles Frederick Hamlett; Christopher Norbert Johnson; Steven John Woodhead; Michael Reader; David C. Rees; Laurence Anne Mevellec; Patrick René Angibaud; Eddy Jean Edgard Freyne; Tom Cornelis Hortense Govaerts; Johan Erwin Edmond Weerts; Timothy Pietro Suren Perera; Ronaldus Arnodus Hendrika Joseph Gilissen; Berthold Wroblowski; Jean Fernand Armand Lacrampe; Alexandra Papanikos; Oliver Alexis Georges Querolle; Elisabeth Thérèse Jeanne Pasquier; Isabelle Noëlle Constance Pilatte; Pascal Bonnet; Werner Constant Johan Embrechts; Rhalid Akkari; Lieven Meerpoel


Archive | 2011

Inhibidores de quinasa de pirazolilquinoxalina

Gordon Saxty; Christopher William Murray; Valerio Berdini; Gilbert Ebai Besong; Christopher Charles Frederick Hamlett; Christopher Norbert Johnson; Steven John Woodhead; Michael Reader; David C. Rees; Laurence Anne Mevellec; Patrick René Angibaud; Eddy Jean Edgard Freyne; Tom Cornelis Hortense Govaerts; Johan Erwin Edmond Weerts; Timothy Pietro Suren Perera; Ronaldus Arnodus Hendrika Joseph Gilissen; Berthold Wroblowski; Jean Fernand Armand Lacrampe; Alexandra Papanikos; Olivier Querolle; Elisabeth Thérèse Jeanne Pasquier; Isabelle Noëlle Constance Pilatte; Pascal Bonnet; Werner Constant Johan Embrechts; Rhalid Akkari; Lieven Meerpoel


Archive | 2011

Dérivés de benzopyrazine substituée en tant qu'inhibiteurs de la fgfr kinase pour le traitement de maladies cancéreuses

Patrick René Angibaud; Valerio Berdini; Gilbert Ebai Besong; Christopher Charles Frederick Hamlett; Yannick Aimé Eddy Ligny; Christopher William Murray; Gordon Saxty; Steven John Woodhead


Archive | 2011

Substituierte benzopyrazinderivate als fgfr-kinaseinhibitoren zur behandlung von krebserkrankungen

Valerio Berdini; Gordon Saxty; Christopher William Murray; Gilbert Ebai Besong; Christopher Charles Frederick Hamlett; Steven John Woodhead; Yannick Aimé Eddy Ligny; Patrick René Angibaud

Collaboration


Dive into the Christopher William Murray's collaboration.

Researchain Logo
Decentralizing Knowledge